S
Wendy Niebler
Vice President, Global Medical Affairs, ADHD, Shire
EDUCATION: DO from Ohio University College ofOsteopathic Medicine, MBA from St. Joseph's University
ACCOMPLISHMENT: Designed Cephalon's largest global clinical program in under two years
On joining the pharma industry:
I started out as a physician in private practice. But the scientific aspect of clinical trial work motivated me to join Cephalon, because I had a chance to not only run, but design, clinical trials. It was an opportunity of a lifetime. As a physician going to industry, you can miss that day-to-day contact with patients. But it's reassuring to know you can impact patients even in a wider sense.
Wendy Niebler
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.